Quantcast

Latest Clinical trial Stories

2014-08-11 08:29:18

Trial Progressing On Track; BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced an update about the Company's Phase III clinical trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer in conjunction with the Company's separate announcement today about certain changes to the Phase III trial. The update from the Company...

2014-08-11 08:28:51

With CE mark in place and FDA-directed studies underway in US, company accelerates market development efforts in US, Canada, Israel, and multiple countries in Europe ENGLEWOOD, Colo., Aug. 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis Diagnostics has expanded its academic and pharmaceutical research network to over 25 sites around the world. To date the company has initiated over 17 scientific and clinical research...

2014-08-08 08:25:48

THE WOODLANDS, Texas, Aug. 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived...

2014-08-07 16:29:04

CUPERTINO, Calif., Aug. 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014. Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9 million and net loss of $5.1 million for the three months ended June 30, 2013. http://photos.prnewswire.com/prnvar/20020717/DRRXLOGO At June 30, 2014, we had cash and investments of $37.3 million, compared...

2014-08-07 16:28:49

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "Trovagene is continuing to demonstrate the benefits of our precision cancer monitoring platform and is progressing toward our commercial roll-out later this year," said Antonius Schuh, Ph.D., chief executive officer of...

2014-08-07 16:28:19

Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones -- Apatorsen -- The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types,...

2014-08-06 23:02:13

Published since 2006, the Orange Paper gives detailed snapshot of clinical trials in Russia. Moscow, Russia (PRWEB) August 06, 2014 Synergy Research Group has released its Q2, 2014 Orange Paper. Published since 2006, the Synergy Orange Paper gives an unbiased and detailed view of the state of clinical trials in Russia. The report, which is issued quarterly, gives a strategic overview and drills down into additional data, such as the number of trials, top companies that initiated studies...

2014-08-05 23:06:59

When researchers at Canada’s McGill University wanted to study the genetic factors affecting chronic pain, they turned to Open Health Network to help. Their clinical study will rely on the tech startup's customizable mobile engagement platform to enable easier, faster data collection for researchers. Los Altos, CA (PRWEB) August 05, 2014 When researchers at Canada’s McGill University wanted to study the genetic factors affecting chronic pain, they turned to Open Health to help....

2014-08-05 16:27:31

GRAND RAPIDS, Mich., Aug. 5, 2014 /PRNewswire/ -- Van Andel Research Institute (VARI) is scheduled to host Rallying to the Challenge, a meeting which highlights the many ways people with Parkinson's disease can impact the clinical trial process and accelerate access to new Parkinson's disease treatments. http://photos.prnewswire.com/prnvar/20140417/76339 The meeting will take place during the third annual Grand Challenges in Parkinson's Disease symposium, one of the most...

2014-08-05 12:31:12

TUCSON, Ariz., Aug. 5, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. This is great news for patients as China is one of the only countries in the world that requires all patient samples be tested in China,...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'